Amitriptyline

NeurAxis Reports Third Quarter 2023 Financial Results

Retrieved on: 
월요일, 11월 20, 2023
Policy, Adolescence, Research, Neuraxis, Percutaneous, Hospital, Record, Abdominal pain, RED, Disability, University, Cyproheptadine, Growth, Publication, Patient, CareFirst BlueCross BlueShield, Amitriptyline, FAPD, Video game

CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.
  • Gross margin totaled 85.9% in the third quarter of 2023, compared to 89.1% in the third quarter of 2022.
  • Selling expenses for the third quarter of 2023 were $64.2 thousand, compared to $81.6 thousand in the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $3,323.4 thousand, compared to $1,586.5 thousand in the third quarter of 2022.

NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders

Retrieved on: 
화요일, 9월 26, 2023
International Classification of Functioning, Disability and Health, Neuraxis, Comparison, Cyproheptadine, FAPD, API, Clinical trial, Amitriptyline, Abdominal pain, FDI, Disability, Patient, Journal of Pain Research, Children's Hospital & Medical Center, Adolescence, Cincinnati, NSS, NYSE, Medical imaging

Led by the Cincinnati Children’s Hospital Medical Center, the comparative study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD.

Key Points: 
  • Led by the Cincinnati Children’s Hospital Medical Center, the comparative study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD.
  • The publication , Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders, featured in the September 19th 2023 Frontiers in Pain Research, reviewed records of 101 adolescents treated with 4 weeks of IB-Stim™, amitriptyline or cyproheptadine.
  • In the study, 59% of patients in the IB-Stim group had failed prior standard medical therapy.
  • Dr. Adrian Miranda, Chief Medical Officer of NeurAxis, said, “It is exciting to see a comparative evaluation of IB-Stim™ with standard medical therapy.

One lot of APO-Amitriptyline recalled due to a nitrosamine impurity

Retrieved on: 
화요일, 2월 7, 2023
Amitriptyline, Patient, NDMA, Risk, Pharmacy, Cancer, Health Canada, Tablet, Protriptyline, Medical device

OTTAWA, ON, Feb. 7, 2023 /CNW/ - Apotex Inc. is recalling one lot of APO-Amitriptyline 10 mg tablets due to the presence of N-nitrosodimethylamine (NDMA), a nitrosamine impurity, above the acceptable limit.

Key Points: 
  • OTTAWA, ON, Feb. 7, 2023 /CNW/ - Apotex Inc. is recalling one lot of APO-Amitriptyline 10 mg tablets due to the presence of N-nitrosodimethylamine (NDMA), a nitrosamine impurity, above the acceptable limit.
  • Patients should continue taking their amitriptyline drug, as the risks from not having adequate treatment outweigh possible effects of exposure to the levels of NDMA seen in the recalled product.
  • This means that long-term exposure to a level above what is considered safe may increase the risk of cancer.
  • Health Canada maintains a list of recalled amitriptyline drugs affected by this issue.

Overdose Overachievers

Retrieved on: 
수요일, 11월 16, 2022
Ranolazine, Wanda, Vomiting, Database, Medicine, Pharmacy, PETS, Adderall, Dog, Amitriptyline, Dietary supplement, Knowledge, Animal, Stomach, Arrhythmia, Veterinarian, Degenerative disease, Bird, Cat, Bradycardia, Poisoning, Potassium, GiFT, Isosorbide, Patient, Veterinary medicine, Metoprolol, Hypotension, Risk, Central nervous system, Pet, CNS, Toxicology, Lethargy, Review, Diagnosis, OTC, Venlafaxine, Medical imaging, Risk management, Pharmaceutical industry, Petunia

MINNEAPOLIS, Nov. 16, 2022 /PRNewswire/ -- When your pet accidentally ingests one of your human medications, it can be of concern. The specific drug may be poisonous to non-humans, or the strength may be dangerous. What happens, however, when a pet accidentally ingests multiple medications? That's when you want the toxicology experts at Pet Poison Helpline by your side.

Key Points: 
  • MINNEAPOLIS, Nov. 16, 2022 /PRNewswire/ -- When your pet accidentally ingests one of your human medications, it can be of concern.
  • Because of its proprietary data and years of experience, the toxicology team has access to answers others simply don't.
  • "It becomes even more challenging for veterinary teams when they're treating a pet who has ingested multiple medications.
  • Not only does the veterinarian need to potentially be concerned about each specific medication, but also its potential interaction with other ingested drugs.

Global Peripheral Neuropathy Market Report 2022: High Prevalence of Chronic Neuropathic Pain Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
월요일, 10월 31, 2022
Pharmaceutical, Health, Physical Therapy, Peripheral neuropathy, Plasmapheresis, Pregabalin, Research, Diabetes, Patient, Cancer, Asia-Pacific, Neuropathic pain, Ageing, Anticonvulsant, Population, HIV/AIDS, Prevalence, Incidence, Gabapentin, Pharmaceutical industry, Amitriptyline, Pfizer

The report offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030.

Key Points: 
  • The report offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030.
  • The drug types studied for analyzing the overall global peripheral neuropathy market are segmented into pharmacological therapies and non-pharmacological therapies.
  • Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.
  • Asia Pacific would exhibit the fastest growth rate in the Global Peripheral Neuropathy market due to aging population, increasing health awareness and high prevalence of the diabetes, cancer and HIV/AIDS.

AlgoTherapeutix Announces Initiation of Global Phase 2 Clinical Trial of ATX01 for the Relief of Pain in Chemotherapy-induced Peripheral Neuropathy in Adults

Retrieved on: 
목요일, 9월 1, 2022
Oncology, FDA, Health, General Health, Pharmaceutical, Biotechnology, Nerve, CEO, Safety, Pain, IND, Toxicity, US Food Sovereignty Alliance, Erythromelalgia, Chemotherapy-induced peripheral neuropathy, Orphan, Amitriptyline, FDA, Adult, Patient, Neuropathic pain, Pharmaceutical industry, EU, CIPN

AlgoTx, a biotechnology company dedicated to developing treatments for complex pain, announced today the initiation of its Phase 2 global clinical trial in Chemotherapy-Induced Peripheral Neuropathy in adult patients.

Key Points: 
  • AlgoTx, a biotechnology company dedicated to developing treatments for complex pain, announced today the initiation of its Phase 2 global clinical trial in Chemotherapy-Induced Peripheral Neuropathy in adult patients.
  • We are excited to begin the ATX01 Phase 2 trial in CIPN, said Stphane Thiroloix, Founder and CEO of AlgoTx.
  • With meaningful efficacy data, we could come a significant step closer to offering millions of patients relief from their debilitating pain.
  • Following successful pre-clinical and phase 1 clinical development, we are eager to confirm our efficacy hypothesis in patients in need of pain relief.

15-Site Trial to Compare Telehealth Cognitive Behavior Therapy Alone and with Medication to Prevent Migraine in Youth

Retrieved on: 
화요일, 7월 26, 2022
American Medical Association, Division, Congress, JAMA, University, View, MPH, Adolescence, Hershey, Doctor of Philosophy, PCORI, Powers, Research, Cincinnati Children's Hospital Medical Center, Patient-Centered Outcomes Research Institute, Cognitive behavioral therapy, Danish Headache Center, COVID-19, Multimedia, The New England Journal of Medicine, CBT, Migraine, Amygdala, Journal, Mental health, Disability, CHAMP, Caregiver, Method, Patient, Neurology, Behavioral medicine, Amitriptyline, Pharmaceutical industry, Health insurance, MD, Headache

The project, to be led by Scott Powers, PhD, Division of Behavioral Medicine and Clinical Psychology, will explore how well cognitive behavior therapy (CBT) delivered by telehealth reduces headache days and disability from migraine compared to CBT telehealth plus a prevention medication (amitriptyline).

Key Points: 
  • The project, to be led by Scott Powers, PhD, Division of Behavioral Medicine and Clinical Psychology, will explore how well cognitive behavior therapy (CBT) delivered by telehealth reduces headache days and disability from migraine compared to CBT telehealth plus a prevention medication (amitriptyline).
  • Cincinnati Children's has played a large role in demonstrating the value of non-medication approaches to treating migraine.
  • With these shifts, more data is needed to determine if medication has an additional benefit beyond CBT aloneespecially when provided via telehealth.
  • This project was selected through a PCORI funding announcement specifically focused on comparing medications and evidence-based nonmedication treatments for migraine.

Lundbeck to Present Data on VYEPTI® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Retrieved on: 
목요일, 6월 9, 2022
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diamond, Woman, Eptinezumab, Neurological disorder, Caregiver, Headache, AHS, Research, Marketing, Lists of diseases, Nausea, Amitriptyline, Disease, Headache (journal), MHD, Steiner, Global Burden of Disease Study, Migraine, Failure, WPAI, CGRP, Disability, Patient, YLD, VAS, Calcitonin gene-related peptide, Topiramate, MSQ, Poster, LUN, Vomiting, Birth control, Pharmaceutical industry, Medical imaging, Aroma compound, Lundbeck, Virtual Private LAN Service

Lundbeck today announced data on VYEPTI (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022.

Key Points: 
  • Lundbeck today announced data on VYEPTI (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022.
  • A total of nine poster presentations will be shared to highlight clinical data and real-world analyses of eptinezumab as a preventive migraine treatment in adults.
  • These data continue to show the clinical benefit of VYEPTI as a preventive treatment option for people with migraine, said Marija Geertsen, M.D., Vice President, U.S. Medical Affairs, Lundbeck.
  • The safety of VYEPTI was evaluated in 2,076 patients with migraine who received at least one dose of VYEPTI.

AlgoTx’s ATX01 Granted Fast Track Designation by FDA for Chemotherapy-Induced Neuropathic Pain

Retrieved on: 
목요일, 6월 9, 2022
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Epothilone, CIPN, Amitriptyline, Food, Toxicity, CEO, Erythromelalgia, Pain, ODD, IND, Multimedia, FDA, Patient, Chemotherapy-induced peripheral neuropathy, Fast Track, Review, Nerve, Quality of life, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, EU

AlgoTx announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA), for the development of ATX01 in chemotherapy-induced neuropathic pain.

Key Points: 
  • AlgoTx announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA), for the development of ATX01 in chemotherapy-induced neuropathic pain.
  • Chemotherapy-induced neuropathic pain is a debilitating condition caused by neurotoxic cancer agents such as platinum derivatives, taxanes, epothilones, plant alkaloids and other drugs.
  • Drugs that are granted this designation are given the opportunity for more frequent interactions with the FDA, as well as potential pathways for expedited approval.
  • AlgoTx is a European biotech founded in 2018 to develop innovative solutions for complex pain, with initial programs focusing on chemotherapy-induced neuropathic pain and erythromelalgia (US and EU ODD granted).

FDA Grants AlgoTx IND Clearance for Phase 2 Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

Retrieved on: 
수요일, 6월 1, 2022
Oncology, Health, FDA, Clinical Trials, Research, Science, Biotechnology, Caregiver, Adult, CIPN, Amitriptyline, Food, CEO, Peripheral neuropathy, Pain, IND, Multimedia, Bpifrance, Cancer, FDA, Brain, Patient, Oncology, Nav1.7, Peripheral nervous system, Neurology, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Spine, Safety, Pharmaceutical industry

European biotech AlgoTx, an innovator in complex pain therapy, today announces the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug Application (IND) for Phase 2 candidate ATX01 in the treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Key Points: 
  • European biotech AlgoTx, an innovator in complex pain therapy, today announces the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug Application (IND) for Phase 2 candidate ATX01 in the treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN).
  • To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
  • FDAs IND clearance opens the way for the planned Phase 2 study, a multi-center, double-blind, randomized, placebo-controlled study of ATX01 in the pain of CIPN in adult cancer survivors.
  • ATX01 is entering Phase 2 in painful peripheral neuropathy.